Author's response to reviews

Title: Experimental and clinical experimental studies on carcinoembryonic antigen-related cell adhesion molecule 1 in non-small-cell lung cancer: how does CEACAM1 manifest

Authors:

Mu-qing Zhou (zhmq0117@gmail.com)
Yan Du (sivy19842003@126.com)
Yi-wen Liu (liuyiwen01@hotmail.com)
Ying-zhi Wang (winniewin@163.com)
Yi-qing He (heyiqing01@msn.com)
Cui-xia Yang (dr.steven@163.com)
Wen-juan Wang (wwjuan@163.com)
Feng Gao (gzmq0117@gmail.com)

Version: 2 Date: 22 January 2013

Author's response to reviews: see over
Dear Editor of *Molecular Cancer*,

I am enclosing here with a manuscript entitled “Clinical and experimental studies on CEACAM1 as a novel NSCLC biomarker” to be considered for publication in *Molecular Cancer*.

In this original study, we focus on carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and Non-small-cell lung cancer (NSCLC) to get a better understanding of both them. First, we measured CEACAM1 levels in serum samples from 69 patients with non-small-cell lung cancer (NSCLC) and age- and sex-matched normal subjects. Moreover, the mRNA expression level of CEACAM1 and its two major isoforms in lung cancer and normal-appearing lung tissue from the same group of people were investigated to study the potential role of CEACAM1 in monitoring NSCLC patients, especially serum CEACAM1 level as tumor marker. To sum up, our findings support the prognostic value of serum CEACAM1, but as a phase I study, our study need to be confirmed in large prospective multicenter collaborative trials.

With the submission of this manuscript and on behalf of all authors contributed to the paper, I declare statements as follows:

1. The paper is being submitted for consideration for publication in *Molecular Cancer*. The material has not been published, whole or in part, and is not under consideration for publication elsewhere.

2. Acknowledgment that all authors have contributed significantly, and that all authors are in agreement with the content of the manuscript. In keeping with the latest guidelines of the International Committee of Medical Journal Editors, each author’s contribution to the paper is to be quantified.

3. There is no any financial support or relationships to this paper that may pose conflict of interest. There are no tables or figures have been reproduced from another source.

4. We will sign Copyright Assignment Form if our paper is accepted by *Molecular Cancer* and mail the Assignment Form to Editorial Office immediately.

5. Contact details: Clinical Laboratory Center, Sixth People’s Hospital Affiliated Shanghai Jiaotong University, 600 Yi-shan Road, Shanghai 200233, P. R. China.
   E-mail: gzmq0117@gmail.com

Thank you!

Sincerely,
Feng Gao, Ph.D

Clinical Laboratory Center,
Sixth People’s Hospital Affiliated Shanghai Jiaotong University,
600 Yi-shan Road, Shanghai 200233, P. R. China.
Tel: 86-21-64369181-8724.
E-mail: gzmq0117@gmail.com